InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (37 ops.)
Discover the detailed record of transactions filed by SEVENTURE PARTNERS SOCIETE ANONYME A DIRECTOIRE, Présidente du Directoire de Seventure Partners. Officer active across 1 companies, notably MAAT PHARMA. In total, 38 filings have been published. Total volume traded: €4m. The latest transaction was disclosed on 27 January 2026 — Cession. Regulator: AMF. The full history is free.
Declarations38 total
€155,33525,423 shares@ €6.110.14% mcap12.2% of flow
ActionEuronext Paris
2026DD1091318·
€351,26257,964 shares@ €6.060.32% mcap27.6% of flow
ActionEuronext Paris
2026DD1091222·
€99,74319,624 shares@ €5.08270.090% mcap7.8% of flow
ActionEuronext Paris
2026DD1088776·
€130,95224,304 shares@ €5.38810.12% mcap10.3% of flow
ActionEuronext Paris
2026DD1088355·
€438,31281,190 shares@ €5.39860.39% mcap34.5% of flow
ActionEuronext Paris
2026DD1088050·
€87,14116,895 shares@ €5.15780.078% mcap6.9% of flow
ActionEuronext Paris
2026DD1087751·
€834104 shares@ €8.0160.0008% mcap0.0% of flow
ActionEuronext Paris
2025DD1018335·
€37346 shares@ €8.10170.0003% mcap0.0% of flow
ActionEuronext Paris
2025DD1018054·
€4,134515 shares@ €8.02630.0037% mcap0.2% of flow
ActionEuronext Paris
2025DD1017875·
€3,262407 shares@ €8.01460.0029% mcap0.1% of flow
ActionEuronext Paris
2025DD1017413·
€3,196398 shares@ €8.02920.0029% mcap0.1% of flow
ActionEuronext Paris
2025DD1017136·
€2,956361 shares@ €8.18850.0027% mcap0.1% of flow
ActionEuronext Paris
2025DD1016915·
€10,6271,278 shares@ €8.31520.0096% mcap0.4% of flow
ActionEuronext Paris
2025DD1016732·
€3,057367 shares@ €8.33040.0028% mcap0.1% of flow
ActionEuronext Paris
2025DD1016734·
€13,0561,599 shares@ €8.16530.012% mcap0.5% of flow
ActionEuronext Paris
2025DD1016429·
€7,580946 shares@ €8.01320.0068% mcap0.3% of flow
ActionEuronext Paris
2025DD1016076·
€4,342542 shares@ €8.01170.0039% mcap0.2% of flow
ActionEuronext Paris
2025DD1015907·
€4,434550 shares@ €8.06110.0040% mcap0.2% of flow
ActionEuronext Paris
2025DD1015693·
€100,90912,564 shares@ €8.03160.091% mcap3.7% of flow
ActionEuronext Paris
2025DD1015398·
€3,261404 shares@ €8.07290.0029% mcap0.1% of flow
ActionEuronext Paris
2025DD1015307·
€2,773307 shares@ €9.03130.0025% mcap0.1% of flow
ActionEuronext Paris
2025DD1014974·
€34,0213,623 shares@ €9.39020.031% mcap1.3% of flow
ActionEuronext Paris
2025DD1014831·
€456 shares@ €7.420.0000% mcap0.0% of flow
ActionEuronext Paris
2024DD999128·
€2,975401 shares@ €7.420.0027% mcap0.1% of flow
ActionEuronext Paris
2024DD998950·
€8,5601,148 shares@ €7.45680.0077% mcap0.3% of flow
ActionEuronext Paris
2024DD998546·
25 of 38 declarations
About SEVENTURE PARTNERS SOCIETE ANONYME A DIRECTOIRE
Isabelle de Crémoux is a French executive widely recognized for her leadership in venture capital and life sciences investing. An engineering graduate from École Centrale Paris, she has built a career spanning more than 25 years at the crossroads of business development, finance, and strategy within the pharmaceutical and health innovation sectors. Before joining Seventure Partners in 2001, she held positions at Arthur Andersen/EY, Pfizer, and Laboratoires Fournier/Abbott, experiences that gave her a strong command of industrial, regulatory, and commercial issues in healthcare. At Seventure Partners, she was instrumental in developing and structuring the firm’s Life Sciences platform, which she now leads. As Chair of the Management Board, she oversees a specialized investment platform focused on biotechnology, connected health, medtech, microbiome-related opportunities, nutrition, and personalized medicine. She is also known for creating Health for Life Capital, described as the first European investment vehicle dedicated to the microbiome, a field in which she has become a reference investor. Her involvement with MaaT Pharma highlights her long-term commitment to innovative companies with significant scientific potential. Seventure Partners has been one of the company’s historic and recurring shareholders, supporting several of its financing milestones. In that setting, Isabelle de Crémoux brings governance expertise, a nuanced understanding of the European biotech landscape, and the ability to support companies through clinical development and toward market access. Her professional profile combines two rare strengths: mastery of investment mechanisms and a strategic understanding of breakthrough innovation in healthcare. She is frequently invited to share her perspective on the microbiome and life sciences investing at international conferences. Through Seventure Partners, she has helped shape a thematic, long-horizon investment approach aimed at backing companies capable of materially improving health and nutrition practices over time.
